...
首页> 外文期刊>Journal of chromatography, B. Analytical technologies in the biomedical and life sciences >Measurement of the anticancer agent gemcitabine and its deaminated metabolite at low concentrations in human plasma by liquid chromatography-mass spectrometry
【24h】

Measurement of the anticancer agent gemcitabine and its deaminated metabolite at low concentrations in human plasma by liquid chromatography-mass spectrometry

机译:液相色谱-质谱法测定人血浆中低浓度的抗癌药吉西他滨及其脱氨基代谢产物

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

A liquid chromatography/mass spectrometry (LC-MS) method has been developed and validated for the determination of the anticancer agent gemcitabine (dFdC) and its metabolite 2',2'-difluoro-2'-deoxyuridine (dFdU) in human plasma. An Oasis HLB solid phase extraction cartridge was used for plasma sample preparation. Separation of the analytes was achieved with a YMC ODS-AQ (5 μm, 120 A, 2.0 mm * 150 mm) column. The initial composition of the mobile phase was 2% methanol/98% 5 mM ammonium acetate at pH 6.8 (v/v), and the flow rate was 0.2 ml/min. An isocratic gradient was used for 3 min, followed by a linear gradient over 4 min to 30% methanol/70% 5 mM ammonium acetate at pH 6.8. The gradient returned to the initial conditions over 2 min and remained there for 6 min. The retention times of dFdC, dFdU, and the internal standard 5'-deoxy-5-fluorouridine (5'-DFUR) were 11.46, 12.63, and 13.58 min. The mass spectrometer was operated under negative electrospray ionization conditions. Single-ion-monitoring (SIM) mode was used for analyte quantitation at m/z 262 for [dFdC–H]~-, m/z 263 for [dFdU–H]~-, and m/z 245 for [5'-DFUR–H]~-. The average recoveries for dFdC, dFdU, and 5'-DFUR were 88.4, 84.6, and 99.3%, respectively. The linear calibration ranges were 5–1000 ng/ml for dFdC, and 5–5000 ng/ml for dFdU. The intra- and inter-assay precisions (%CV) were ≤3 and ≤7% at three concentration levels (50.0, 500, and 5000 ng/ml). The limits of quantitation (defined as 10 times of signal-to-noise ratio) were 3.16 ng/ml for dFdC, and 1.35 ng/ml for dFdU with 50-l sample injections. This method has been used for measuring plasma concentrations of dFdC and dFdU in samples from adult cancer patients in a Phase I trial of weekly dFdC given as 150 (or lower) mg/(m~2 24-h) infusion. The average plasma dFdC concentrations at 22- and 23-h into the infusion were 18.3 and 16.8 ng/ml at 150 and 100 mg/m2, respectively; the values for dFdU averaged 2950 and 1372 ng/ml.
机译:已经开发了液相色谱/质谱(LC-MS)方法,并已用于测定人血浆中抗癌药吉西他滨(dFdC)及其代谢物2',2'-二氟-2'-脱氧尿苷(dFdU)的方法得到验证。 Oasis HLB固相萃取柱用于血浆样品的制备。使用YMC ODS-AQ(5μm,120 A,2.0 mm * 150 mm)色谱柱实现分析物的分离。流动相的初始组成为2%甲醇/ 98%5 mM醋酸铵,pH 6.8(v / v),流速为0.2 ml / min。使用等度梯度洗脱3分钟,然后在4分钟内线性梯度洗脱至30%甲醇/ 70%5 mM乙酸铵(pH 6.8)。梯度在2分钟内恢复到初始条件,并在此保持6分钟。 dFdC,dFdU和内标5'-脱氧-5-氟尿苷(5'-DFUR)的保留时间分别为11.46、12.63和13.58分钟。质谱仪在负电喷雾电离条件下运行。单离子监测(SIM)模式用于[dFdC–H]〜-的m / z 262,[dFdU–H]〜-的m / z 263和[5'的m / z 245。 -DFUR–H]〜-。 dFdC,dFdU和5'-DFUR的平均回收率分别为88.4%,84.6和99.3%。 dFdC的线性校准范围为5–1000 ng / ml,dFdU的线性校准范围为5–5000 ng / ml。在三个浓度水平(50.0、500和5000 ng / ml)下,测定内和测定间精密度(%CV)≤3和≤7%。定量限(定义为信噪比的10倍)对于dFdC为3.16 ng / ml,对dFdU为50进样量的1.35 ng / ml。在每周一次dFdC的I期试验中,以150(或更低)mg /(m〜2 24-h)的剂量输注,该方法已用于测量成年癌症患者样品中dFdC和dFdU的血浆浓度。分别在150和100 mg / m2时,输注22和23 h的血浆dFdC平均浓度分别为18.3和16.8 ng / ml。 dFdU的平均值为2950和1372 ng / ml。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号